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BiTE® antibodies are novel recombinant single chain Ig
domain constructs that leverage the endogenous cytotoxic
potential of polyclonal T cells to target malignant cells by
utilizing the specific binding properties of variable
domains from two different antibodies. Antibody-based
immunotherapy represents a promising strategy in cancer.
BiTE® antibodies have demonstrated efficacy in hematolo-
gic malignancies, both preclinically and clinically.
Two investigational BiTE antibodies are under develop-
ment targeting leukemia. The most advanced BiTE®
antibody, Blinatumomab, directs cytotoxic T cells to
CD19-expressing target cells. Blinatumomab has shown
anti-leukemia activity in adult relapsed/refractory (r/r)
B-precursor ALL. Its efficacy and toxicity was evaluated
in a large confirmatory Phase II study. Patients with
Ph-negative r/r ALL (N = 189; refractory; 1st relapse
Given the anti-leukemia activity of single-agent Blinatu-
momab in a difficult-to-treat population with r/r ALL,
another BiTE® antibody targeting CD33, AMG 330, was
developed for its suitability as immunotherapy in AML.
To simulate the natural setting of target and T cells in
AML patients, a long-term culture system was developed
that supports the growth of primary AML cells ex-vivo for
up to 5 weeks. AMG 330 activated and expanded residual
autologous T cells within primary AML patient samples
and eliminated CD33+ blasts even at very low effector to
target ratios. The functional relevance of CD33 expression
levels was shown by faster lysis kinetics of CD33BRIGHT
versus CD33DIM AML cell lines and primary AML cells in
ex-vivo cytotoxicity assays. However, by extending the
exposure time to AMG 330, potent anti-leukemic activity
was observed in both CD33BRIGHT and CD33DIM cells.
AMG 330 treated T cells were shown to up-regulate the
activation markers CD25, PD-1, TIM3 and LAG3,
which was partially reversible after complete target cell
elimination
Clinical experience with Blinatumomab in ALL and
ex-vivo activity of AMG 330 in primary AML samples
supports further development of BiTE® antibodies for
targeted T cell-mediated immunotherapy of patients with
malignancies.
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